What is the appropriate evaluation and management for a patient with elevated red blood cell count, elevated hematocrit, and an elevated free androgen index?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Evaluation and Management of Elevated RBC, Elevated HCT, and Elevated Free Androgen Index

This presentation in a female patient most likely represents polycystic ovary syndrome (PCOS) with secondary erythrocytosis from hyperandrogenism, requiring immediate endocrine workup to exclude androgen-secreting tumors and other serious causes before initiating treatment.

Initial Diagnostic Approach

The combination of elevated hematocrit with elevated free androgen index suggests androgen-induced erythrocytosis. Your immediate priority is determining the source and severity of hyperandrogenism, as this drives both morbidity and mortality risk.

Critical First Steps

Measure early morning (before 9 AM) plasma total testosterone on days 4-10 of the menstrual cycle 1. This timing is essential as norms are standardized for this window. If total testosterone is normal but clinical suspicion remains high (progression of symptoms, risk factors present), recheck with both total and free testosterone at a reliable specialty laboratory 1.

Essential Concurrent Testing

The following tests must be obtained to exclude life-threatening causes 1:

  • Pregnancy test (if amenorrheic)
  • Pelvic ultrasonography to detect ovarian neoplasm or polycystic ovaries
  • DHEAS (dehydroepiandrosterone sulfate) to assess for adrenal source
  • Early morning 17-hydroxyprogesterone to exclude congenital adrenal hyperplasia, especially in high-risk ethnic groups (Ashkenazi Jews 1:27, Hispanics 1:40, Slavics 1:50)
  • Prolactin level to exclude hyperprolactinemia

Risk Stratification for Serious Pathology

Androgen-secreting tumors occur in 0.2% of hyperandrogenic women, with over half being malignant 1. Red flags requiring urgent evaluation include:

  • Rapid onset or progression of symptoms
  • Virilization (clitoromegaly, deepening voice, male-pattern baldness)
  • Very high testosterone levels (typically >200 ng/dL suggests tumor)
  • Palpable adnexal mass

If DHEAS is markedly elevated, obtain adrenal CT imaging to exclude adrenal neoplasm 1.

Understanding the Erythrocytosis Connection

Androgens stimulate erythropoiesis, leading to elevated RBC count and hematocrit 2, 3. This is a direct physiologic effect of testosterone on red blood cell production. The elevated hematocrit in your patient is likely secondary to the hyperandrogenism rather than a primary hematologic disorder.

When to Pursue Primary Hematologic Workup

If the patient has isolated erythrocytosis without other cytopenias or thrombocytosis, secondary causes (including androgen excess) should be investigated first 2. However, if erythrocytosis is accompanied by leukocytosis or thrombocytosis, immediately test for JAK2 mutations and serum erythropoietin levels to exclude polycythemia vera 2, 4.

Most Likely Diagnosis: PCOS

PCOS is the most common cause of hyperandrogenism 1. Look for these associated features:

  • Menstrual irregularity or anovulation (most common presentation)
  • Central obesity with increased waist-to-hip ratio
  • Acanthosis nigricans (brown hyperpigmentation on neck, axillae)
  • Abnormal carbohydrate metabolism (40% have impaired glucose tolerance if obese) 5
  • Family history of type 2 diabetes
  • Infertility

The diagnosis is confirmed when testosterone elevation occurs with anovulatory symptoms or polycystic ovaries on ultrasound, after excluding other causes 1.

Additional Metabolic Assessment

Given the strong association between PCOS and metabolic syndrome, obtain 5:

  • Fasting glucose and lipid panel
  • Body mass index and waist-to-hip ratio (WHR >0.8 is abnormal in women)
  • Screen for insulin resistance

Management Strategy

Immediate Actions

  1. If hematocrit >54%, consider therapeutic phlebotomy while investigating the underlying cause 6. This threshold is used in testosterone therapy monitoring and applies to androgen-induced erythrocytosis.

  2. Weight reduction is first-line therapy if obesity is present. As little as 7% body weight loss can restore ovulation, decrease androgen levels, increase SHBG, and improve hirsutism 5.

Definitive Treatment Based on Source

For glucocorticoid-suppressible hyperandrogenism (predominantly adrenal source confirmed by dynamic testing):

  • Dexamethasone 0.25-0.5 mg or prednisone 5-7.5 mg daily after supper for 2-3 months 5
  • Treatment for 1-2 years may yield long-term remission 5

For PCOS or predominantly ovarian hyperandrogenism:

  • Oral contraceptives with antiandrogen properties (first-line for non-fertility seeking patients) 5
  • Insulin-sensitizing agents (metformin, thiazolidinediones) for those with severe PCOS, insulin resistance, obesity, or acanthosis nigricans 5
  • Antiandrogens (spironolactone, flutamide) - note these are not FDA-approved for this indication and are contraindicated in pregnancy 5

Monitoring the Hematocrit

Recheck hematocrit 3 months after initiating androgen-lowering therapy, then annually 6. The hematocrit should normalize as testosterone levels decrease. If it remains elevated despite normalized androgens, pursue primary hematologic evaluation.

Critical Pitfalls to Avoid

  1. Do not use commercial laboratories for testosterone measurement - many provide inaccurate results with unreliable reference ranges 5. Use only specialty laboratories experienced in measuring low female testosterone levels.

  2. Do not assume mild symptoms are benign - early diagnosis and treatment prevent progression of hirsutism, metabolic complications, and infertility 5.

  3. Do not start oral contraceptives without determining the androgen source - this treats symptoms but may miss serious underlying pathology like tumors 5.

  4. Do not ignore the cardiovascular and metabolic risks - women with PCOS have increased risk of diabetes, hypertension, dyslipidemia, and potentially cardiovascular disease requiring long-term monitoring 5.

  5. Do not forget that discontinuation of hormonal therapy leads to recurrence - patients need counseling about long-term treatment requirements 5.

Long-term Surveillance

Even after successful treatment, maintain vigilance for 5:

  • Development of type 2 diabetes
  • Dyslipidemia
  • Hypertension
  • Cardiovascular disease
  • Recurrence of hyperandrogenemia after therapy discontinuation

References

4
Research

[Diagnostic work-up of erythrocytosis].

La Revue de medecine interne, 2026

5
Guideline

american association of clinical endocrinologists medical guidelines for the clinical practice for the diagnosis and treatment of hyperandrogenic disorders.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2001

6
Guideline

testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2018

Related Questions

What are the recommended evaluations and management for a 40-year-old male with persistently elevated hemoglobin and hematocrit?
What is the differential diagnosis, workup, and management for a female patient with elevated red blood cell count (5.77 million/µL), hemoglobin (17.2 g/dL), and hematocrit (52.6 %)?
For a patient with elevated red blood cell count, elevated hematocrit, low mean corpuscular hemoglobin, fasting glucose of 118 mg/dL, AST 60 U/L, ALT 106 U/L, total testosterone 75 ng/dL, hemoglobin A1c 6.2 %, and vitamin D 10.9 ng/mL, what is the interpretation of these labs and what management steps should be taken?
What is the appropriate management for a 17-year-old male with elevated red blood cell count, hemoglobin, and hematocrit?
What are the next steps for a 65-year-old asymptomatic patient with elevated hemoglobin, elevated hematocrit, and elevated red blood cell count?
Does the interaction between iron and levothyroxine occur only with oral iron taken together with tablet levothyroxine, and not with intravenous iron or liquid levothyroxine?
What inflammatory arthritis presents with joint pain that improves with movement and worsens at rest?
What is an appropriate trial dose of liquid levothyroxine for a patient with a thyroid‑stimulating hormone (TSH) level of 4.9 mIU/L, a free thyroxine (free T4) level of 1.2 ng/dL, and iron‑deficiency anemia?
What is the appropriate melatonin dose for a patient aged 80 years or older?
Should a 57-year-old patient with asthma receive the 23-valent pneumococcal polysaccharide vaccine (PPSV23)?
In a patient on levothyroxine who requires iron supplementation, how should I manage treatment when IV iron is not available?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.